Preclinical, phase 1 & phase 2 trials have indicated that<unk>  exhibits similar adverse effects to other established GLP-1 receptor agonists, such as GLP-1 receptor agonist dulaglutide. These effects occur largely within the gastrointestinal tract. The most frequently observed adverse effects are nausea, diarrhoea and vomiting which were linked to dosage amount (i.e. higher likelihood the higher the dose). The amount of patients who discontinued taking<unk>  also increased as dosage increased, with patients taking 15 mg having a 25% discontinuation rate vs 5.1% for 5 mg patients and 11.1% for dulaglutide. To a slightly lesser extent, patients also reported reduced appetite. Other side effects reported were dyspepsia, constipation, abdominal pain, dizziness and hypoglycaemia.
Tirzepatide
Plecanatide
Oprelvekin
Vosoritide
Lixisenatide
Abaloparatide
Bulevirtide
Eptifibatide